MX366342B - Forma solida de un derivado de dihidro-pirido-oxazina. - Google Patents

Forma solida de un derivado de dihidro-pirido-oxazina.

Info

Publication number
MX366342B
MX366342B MX2015006650A MX2015006650A MX366342B MX 366342 B MX366342 B MX 366342B MX 2015006650 A MX2015006650 A MX 2015006650A MX 2015006650 A MX2015006650 A MX 2015006650A MX 366342 B MX366342 B MX 366342B
Authority
MX
Mexico
Prior art keywords
pyrido
dihydro
solid form
oxazine derivative
forms
Prior art date
Application number
MX2015006650A
Other languages
English (en)
Other versions
MX2015006650A (es
Inventor
Kammertoens Karen
Soldermann Nicolas
Zecri Frédéric
Hurth Konstanze
Kalis Christoph
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51019963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366342(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015006650A publication Critical patent/MX2015006650A/es
Publication of MX366342B publication Critical patent/MX366342B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con una forma cristalina anhidra de (1,1- dioxo-hexahidro-1-lambda*6*tiopiran-4il)-{(S)-3-[1-(6-metoxi -5-metil-piridin-3-iI)-2,3-dihidro-1H-pirido[3,4-b][1,4]oxazin-7- iloxi]-pirrolidin-1-il}metanona; composiciones farmacéuticas y combinaciones incluyendo estas formas, así como a métodos de uso de estas formas, incluyendo sus composiciones farmacéuticas y combinaciones para el tratamiento de enfermedades.
MX2015006650A 2012-11-26 2013-11-26 Forma solida de un derivado de dihidro-pirido-oxazina. MX366342B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GC201222895 2012-11-26
IR1391307213 2012-12-04
PCT/IB2013/060412 WO2014102630A1 (en) 2012-11-26 2013-11-26 Solid form of dihydro-pyrido-oxazine derivative

Publications (2)

Publication Number Publication Date
MX2015006650A MX2015006650A (es) 2015-08-10
MX366342B true MX366342B (es) 2019-07-05

Family

ID=51019963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006650A MX366342B (es) 2012-11-26 2013-11-26 Forma solida de un derivado de dihidro-pirido-oxazina.

Country Status (23)

Country Link
EP (1) EP2928896B1 (es)
KR (1) KR102184069B1 (es)
CN (1) CN104870451B (es)
AU (1) AU2013368997B8 (es)
BR (1) BR112015009870A2 (es)
CA (1) CA2891521A1 (es)
CL (1) CL2015001409A1 (es)
CY (1) CY1119702T1 (es)
DK (1) DK2928896T3 (es)
GT (1) GT201500124A (es)
HK (1) HK1209419A1 (es)
IL (1) IL238889B (es)
MX (1) MX366342B (es)
NZ (1) NZ706865A (es)
PE (1) PE20150946A1 (es)
PH (1) PH12015501052A1 (es)
PL (1) PL2928896T3 (es)
PT (1) PT2928896T (es)
SG (1) SG11201503410VA (es)
TN (1) TN2015000128A1 (es)
TW (1) TW201422625A (es)
WO (1) WO2014102630A1 (es)
ZA (1) ZA201502350B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200286A (es) 2011-12-22 2020-09-23 Novartis Ag DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MA53219A (fr) 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
SK398A3 (en) 1995-07-06 1998-07-08 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
WO1998010121A1 (en) 1996-09-06 1998-03-12 Obducat Ab Method for anisotropic etching of structures in conducting materials
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
PE20020544A1 (es) 2000-11-07 2002-07-30 Novartis Ag Derivados de indolilmaleimida
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
BR0317099A (pt) 2002-12-09 2005-10-25 Boardd Of Regents Of The Unive Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
UA96736C2 (ru) * 2005-09-07 2011-12-12 Мерк Сероно Са Ингибиторы pi3k для лечения эндометриоза
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
CR20200286A (es) * 2011-12-22 2020-09-23 Novartis Ag DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)

Also Published As

Publication number Publication date
ZA201502350B (en) 2017-08-30
HK1209419A1 (en) 2016-04-01
GT201500124A (es) 2016-03-01
CA2891521A1 (en) 2014-07-03
MX2015006650A (es) 2015-08-10
CL2015001409A1 (es) 2015-07-24
AU2013368997A1 (en) 2015-04-30
PE20150946A1 (es) 2015-06-28
IL238889B (en) 2021-03-25
EP2928896B1 (en) 2017-07-19
EP2928896A1 (en) 2015-10-14
CY1119702T1 (el) 2018-06-27
PL2928896T3 (pl) 2018-01-31
PT2928896T (pt) 2017-10-25
AU2013368997B2 (en) 2015-09-24
WO2014102630A1 (en) 2014-07-03
DK2928896T3 (da) 2017-11-06
IL238889A0 (en) 2015-07-30
AU2013368997B8 (en) 2015-10-08
CN104870451B (zh) 2017-07-07
PH12015501052A1 (en) 2015-07-27
SG11201503410VA (en) 2015-05-28
TW201422625A (zh) 2014-06-16
NZ706865A (en) 2016-04-29
TN2015000128A1 (en) 2016-10-03
BR112015009870A2 (pt) 2017-12-05
CN104870451A (zh) 2015-08-26
AU2013368997A8 (en) 2015-10-08
KR20150091047A (ko) 2015-08-07
KR102184069B1 (ko) 2020-11-30

Similar Documents

Publication Publication Date Title
NZ700928A (en) Dna-pk inhibitors
MY193728A (en) Muscarinic receptor agonists
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
IN2014CN03597A (es)
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
PH12015500310A1 (en) Pyrrolopyrazoles as n-type calcium channel blockers
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12017500595B1 (en) Aldosterone synthase inhibitors
IN2012DN03846A (es)
CY1119702T1 (el) Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
GB201209015D0 (en) Novel compounds
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
PH12015500314A1 (en) Cyclopentylpyrazoles as n-type calcium channel blockers
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
EA201591023A1 (ru) Твердая форма производного дигидропиридооксазина
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
MX2014002343A (es) Inhibidores de parp.

Legal Events

Date Code Title Description
FG Grant or registration